Academia Journal of Medicine
Year 2026, Volume-9, Issue- 1 (January- June)

www.acspublisher.com

Three-Dimensional Organoids in Oral Cancer Research: A Paradigm Shift in Oncology

Prachi Hazari[1]*, Brijesh Byrappa[2], Sai Sagar[3], Kishor Patil[4] and Anviti Kalekar[5]

[1]Reader, Department of Pediatric and Preventive Dentistry, Nanded Rural Dental College and Research Centre, Nanded, Maharashtra, India
[2]Dental Surgeon & Implantologist, Dental Experts – A Super Speciality Dental Clinic, Bangalore, Karnataka, India
[3]Senior House Surgeon, Government Hospital Neyattinkara, Trivandrum, Kerala, India
[4]Associate Professor, Department of Oral Pathology and Microbiology, SMBT Dental College, Sangamner, Maharashtra, India
[5]Raja Rajeswari Dental College and Hospital, Karnataka, India

ARTICLE INFO

Keywords: Organoids, Oral cancer, OSCC, 3D culture, Personalized medicine

doi:10.48165/ajm.2026.9.01.32

ABSTRACT

Oral cancer, predominantly oral squamous cell carcinoma (OSCC), remains a major global health burden with high morbidity and mortality rates. Traditional two-dimensional (2D) cell cultures and animal models often fail to accurately replicate tumor heterogeneity and the complex tumor microenvironment. Organoids, three-dimensional (3D) in vitro culture systems derived from stem cells or tumor tissues, have emerged as a revolutionary tool in cancer research. Oral cancer organoids closely mimic the histological architecture, genetic profile, and functional characteristics of the original tumor. This review discusses the concept, development, methodologies, and applications of organoids in oral cancer research, highlighting their role in disease modeling, drug screening, and personalized medicine. Additionally, limitations, challenges, and future prospects are addressed.

Introduction

Oral cancer, particularly oral squamous cell carcinoma (OSCC), accounts for over 90% of malignancies in the oral cavity. Despite advancements in diagnostic and therapeutic strategies, the 5-year survival rate remains relatively low due to late-stage diagnosis, recurrence, and metastasis.[1,2]

Conventional research models such as 2D cell cultures and animal models have limitations in replicating tumor complexity, heterogeneity, and microenvironmental interactions. In recent years, organoid technology has emerged as a promising alternative, offering a more physiologically relevant model for studying cancer biology.[3]

Organoids are self-organizing 3D cellular structures derived from stem cells or primary tumor tissues that recapitulate key features of the original organ or tumor. Their application in oral cancer research is rapidly expanding, providing new insights into tumor progression, drug response, and personalized treatment strategies.[4,5]

Concept of Organoids: Organoids are three-dimensional, self-organizing cellular structures grown in vitro that closely mimic the architecture, cellular composition, and functional characteristics of their tissue of origin. Unlike conventional two-dimensional cell cultures, organoids provide a more physiologically relevant model by recreating key aspects of the in vivo microenvironment. They are typically derived from various cell sources, including embryonic stem cells (ESCs), adult stem cells (ASCs), induced pluripotent stem cells (iPSCs), and patient-derived tumor cells, each offering unique advantages in terms of differentiation potential and disease modeling. These cells are embedded within a supportive three-dimensional extracellular matrix, commonly Matrigel, which provides structural scaffolding and biochemical cues essential for growth. In addition, the culture medium is supplemented with specific growth factors such as epidermal growth factor (EGF), Noggin, and R-spondin, which regulate

Corresponding author: Prachi Hazari
Email id: prachisiingh@gmail.com

cell proliferation, differentiation, and spatial organization. Through these conditions, cells undergo self-renewal and differentiation, leading to the formation of complex, multicellular structures that recapitulate the histological and genetic features of the original tissue. This ability to preserve tissue-specific functionality and heterogeneity makes organoids a powerful tool for studying development, disease mechanisms, and therapeutic responses, particularly in cancer research.[6-8]

Development of Oral Cancer Organoids: The development of oral cancer organoids is a multi-step process that enables the in vitro recreation of tumor architecture and biology. It begins with tissue collection, where tumor samples are obtained either through biopsy or surgical resection under sterile conditions. These samples are then subjected to tissue processing, which involves mechanical mincing and enzymatic digestion to dissociate the tumor into single cells or small cell clusters. This step is crucial for isolating viable tumor cells while preserving their biological characteristics.

Following this, the isolated cells are introduced into a three-dimensional (3D) culture system, where they are embedded within an extracellular matrix scaffold such as Matrigel. This matrix provides structural support and mimics the native tumor microenvironment. The cells are cultured in a defined medium enriched with essential growth factors, including epidermal growth factor (EGF), Noggin, and R-spondin, which promote cell proliferation, differentiation, and maintenance of stemness.

Under these optimized conditions, cells undergo organoid formation, where they proliferate and self-organize into three-dimensional structures that closely resemble the histological and genetic features of the original tumor. These organoids maintain tumor heterogeneity and functional characteristics, making them highly valuable for research applications. Finally, organoids can be subjected to expansion and cryopreservation, allowing them to be passaged multiple times and stored for long-term use. This ensures a sustainable and reproducible model system for studying oral cancer biology, drug responses, and personalized therapeutic strategies. [6-10]

Characteristics of Oral Cancer Organoids[11,12]

Histological Similarity: Oral cancer organoids closely mimic the three-dimensional architecture of the original tumor tissue. They reproduce key histological features such as cell arrangement, differentiation patterns, and tissue organization, allowing researchers to study tumor morphology in a more physiologically relevant context compared to conventional two-dimensional cultures.

Genetic Fidelity: Organoids retain the genetic profile of the parent tumor, including specific mutations, gene expression patterns, and molecular signatures. This preservation of genomic integrity is essential for understanding tumor biology, identifying therapeutic targets, and evaluating mutation-specific treatment responses.

Tumor Heterogeneity: One of the most significant advantages of organoids is their ability to maintain intra-tumoral heterogeneity. They preserve diverse cell populations present within the tumor, including cancer stem cells and different subclones, thereby reflecting the complexity and variability of oral cancer more accurately than traditional models.

Functional Relevance: Oral cancer organoids exhibit functional behavior similar to the original tumor, particularly in their response to therapeutic agents. This enables their use in drug screening and sensitivity testing, providing insights into patient-specific treatment outcomes and supporting the development of personalized medicine approaches.

Applications of Organoids in Oral Cancer Research[13-15]

Disease Modeling: Organoids serve as robust in vitro models that closely replicate the biological behavior of oral tumors. They enable detailed investigation of key processes such as tumor initiation, progression, and metastasis under controlled laboratory conditions. By preserving the structural and molecular characteristics of the original tumor, organoids provide a more accurate platform for understanding the pathogenesis and evolution of oral cancer.

Drug Screening and Testing: One of the most significant applications of organoids is in high-throughput drug screening. These models allow researchers to evaluate the efficacy of multiple anticancer agents simultaneously, facilitating the identification of effective therapies. Additionally, organoids help in studying mechanisms of drug resistance, thereby contributing to the development of more targeted and effective treatment strategies.

Personalized Medicine: Patient-derived organoids (PDOs) have opened new avenues in precision oncology. By testing various therapeutic options on organoids derived from an individual patient's tumor, clinicians can predict treatment responses and tailor therapies accordingly. This approach enhances treatment efficacy while minimizing unnecessary side effects.

Tumor Microenvironment Studies: Organoids can be co-cultured with stromal cells, immune cells, and other components of the tumor microenvironment to better simulate in vivo conditions. This allows researchers to study complex cellular interactions, immune responses, and the role of the microenvironment in tumor growth and therapeutic resistance.

Biomarker Discovery: Organoids provide an excellent platform for the identification and validation of diagnostic and prognostic biomarkers. By analyzing molecular changes and treatment responses in organoids, researchers can discover novel biomarkers that aid in early detection, prognosis assessment, and therapeutic decision-making in oral cancer.

Table 1: Comparison of Conventional Models and Organoids in Oral Cancer Research

Feature	2D Cell Culture	Animal Models	Organoids
Structure	Flat monolayer	Complex whole organism	3D architecture
Tumor Microenvironment	Poorly mimicked	Partially mimicked	Better simulated
Genetic Fidelity	Limited	Moderate	High
Tumor Heterogeneity	Lost	Partially retained	Well preserved
Drug Response Prediction	Low accuracy	Moderate	High accuracy
Ethical Concerns	Minimal	High	Moderate
Cost	Low	High	Moderate to High
Time Efficiency	High	Low	Moderate

Advantages of Organoids: Organoids offer several significant advantages over traditional experimental models in oral cancer research. One of their primary strengths is their ability to more accurately mimic in vivo conditions compared to conventional two-dimensional (2D) cultures, as they recreate the three-dimensional architecture and cellular interactions of the tumor. They also maintain genetic and phenotypic stability, preserving the molecular characteristics of the original tumor over multiple passages. Additionally, organoids help reduce dependence on animal models, thereby addressing ethical concerns and improving translational relevance. Their capacity to reflect patient-specific tumor behavior makes them highly valuable in personalized treatment strategies, allowing tailored therapeutic approaches. Furthermore, organoids are suitable for long-term studies, as they can be expanded and maintained over extended periods without significant loss of functionality.

Limitations and Challenges: Despite their promising applications, organoids are associated with several limitations and challenges. A major drawback is the lack of full vascularization, which restricts nutrient diffusion and limits the ability to fully replicate in vivo tumor physiology. They also exhibit limited immune system representation, making it difficult to study immune-tumor interactions unless co-culture systems are incorporated. The development and maintenance of organoids involve high costs and technical complexity, requiring specialized materials and expertise. Additionally, there is variability in culture protocols, which can affect reproducibility and standardization across different laboratories. Finally, the use of patient-derived samples raises ethical considerations related to consent, data privacy, and biobanking, which must be carefully addressed in clinical research settings.

Future Perspectives: The future of organoids in oral cancer research is highly promising, with continuous advancements expanding their scope and clinical relevance. Integration with microfluidic technologies (organs-on-chip) is expected to enhance the physiological accuracy of organoid models by enabling controlled simulation of blood flow, nutrient exchange, and mechanical forces. The incorporation of immune components into organoid systems will allow more comprehensive studies of tumor–immune interactions, particularly in the context of immunotherapy. Furthermore, the application of CRISPR-based gene editing offers powerful opportunities to investigate gene function, model genetic mutations, and explore targeted therapeutic strategies.

Efforts are also being directed toward the development of standardized culture protocols, which will improve reproducibility and facilitate wider adoption in research and clinical settings. Importantly, organoids are increasingly being explored for clinical decision-making, where patient-derived models can guide personalized treatment selection and predict therapeutic outcomes. In addition, advancements in bioengineering and artificial intelligence (AI) are expected to further refine organoid technology by improving data analysis, predictive modeling, and automation, thereby enhancing their overall utility in precision oncology.

Conclusion

Organoids represent a transformative advancement in oral cancer research, effectively bridging the gap between traditional in vitro models and clinical reality. Their ability to closely mimic tumor biology, preserve genetic heterogeneity, and accurately predict drug responses makes them invaluable tools in the era of precision oncology. By providing a more reliable and patient-specific platform, organoids have the potential to significantly improve our understanding of oral cancer and optimize therapeutic strategies. Although certain limitations and challenges persist, ongoing technological innovations and interdisciplinary approaches are likely to establish organoids as a cornerstone in future oral cancer research and personalized treatment paradigms.

References

Tan Y, Wang Z, Xu M, Li B, Huang Z, Qin S, Nice EC, Tang J, Huang C. Oral squamous cell carcinomas: state of the field and emerging directions. **Int J Oral Sci.** 2023;15(1):44. doi:10.1038/s41368-023-00227-1.

Bagan J, Sarrion G, Jimenez Y. Oral cancer: clinical features. **Oral Oncol.** 2010;46(6):414–417. doi:10.1016/j.oraloncology.2010.03.017.

Esposito A, Ferraresi A, Vallino L, Garavaglia B, Dhanasekaran DN, Isidoro C. Three-dimensional in vitro cell cultures as a feasible and promising alternative to two-dimensional and animal models in cancer research. **Int J Biol Sci.** 2024;20(13):5293–5311.

Yang S, Hu H, Kung H, Zou R, Dai Y, Hu Y, Wang T, Lv T, Yu J, Li F. Organoids: the current status and biomedical applications. **MedComm (2020).** 2023;4(3):e274. doi:10.1002/mco2.274.

Fan H, Demirci U, Chen P. Emerging organoid models: leaping forward in cancer research. **J Hematol Oncol.** 2019;12(1):142. doi:10.1186/s13045-019-0812-4.

Wu Y, Li X, Liu H, Yang X, Li R, Zhao H, et al. Organoids in the oral and maxillofacial region: present and future. **Int J Oral Sci.** 2024;16(1):61. doi:10.1038/s41368-024-00278-5.

Gao X, Wu Y, Liao L, Tian W. Oral organoids: progress and challenges. **J Dent Res.** 2021;100(5):454–463. doi:10.1177/0022034520977734.

Li FC, Kishen A. 3D organoids for regenerative endodontics. **Biomolecules.** 2023;13(6):900. doi:10.3390/biom13060900.

Driehuis E, et al. Patient-derived oral mucosa organoids as an in vitro model for methotrexate-induced toxicity in pediatric acute lymphoblastic leukemia. **PLoS One.** 2020;15(5):e0231588. doi:10.1371/journal.pone.0231588.

Hisha H, Tanaka T, Ueno H. Lingual epithelial stem cells and organoid culture of them. **Int J Mol Sci.** 2016;17(2):168. doi:10.3390/ijms17020168.

Lee MR, Kang S, Lee J, Kong SY, Kim Y, Lee YS, Shon HW, Kang G, Lee J, Youn SM, Kwack DW, Park JY, Kim SM, Choi W, Lee JH, Shin D, Kwon IJ, Choi SW, Kim YH. Organoid morphology-guided classification for oral cancer reveals prognosis. **Cell Rep Med.** 2025;6(5):102129. doi:10.1016/j.xcrm.2025.102129.

Wang Y, Sun X, Lu B, Zhang D, Yin Y, Liu S, Chen L, Zhang Z. Current applications, future perspectives and challenges of organoid technology in oral cancer research. **Eur J Pharmacol.** 2025;993:177368. doi:10.1016/j.ejphar.2025.177368.

Varinelli L, Illescas O, Lorenc EJ, Battistessa D, Di Bella M, Zanutto S, Gariboldi M. Organoids technology in cancer research: from basic applications to advanced ex vivo models. **Front Cell Dev Biol.** 2025;13:1569337. doi:10.3389/fcell.2025.1569337.

Huang C, Sanaei F, Verdurmen WPR, Yang F, Ji W, Walboomers XF. The application of organs-on-a-chip in dental, oral, and craniofacial research. **J Dent Res.** 2023;102(4):364–375. doi:10.1177/00220345221143264.

Thalakiriyawa DS, Dissanayaka WL. Advances in regenerative dentistry approaches: an update. **Int Dent J.** 2024;74(1):25–34. doi:10.1016/j.identj.2023.07.002.